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The six studies analyzed included one randomized control trial
(RCT) study, one cohort study, and four case control studies.
An analysis of gut microbiota composition and UPDRS (Unified
Parkinson’s Disease Rating Scale) scores were used as
outcome measurements in most of the studies. Some studies
also included other outcome parameters such as short chain
fatty acids (SCFA) and metabolic protein levels.
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Every year, approximately 50,000 people are diagnosed with PD, resulting
in 500,000 people living with the disease at any given time in the U.S. PD
is a neurodegenerative disease resulting from the loss of nerve cells that
secrete dopamine, an important neurotransmitter that plays an essential
role in rewards and behavior, pleasure, and motor function. Without this
essential neurotransmitter, medical conditions such as PD can develop,
affecting motor function. Current available treatment focuses on
compensating for dopamine deficiency, primarily Levodopa, a precursor to
dopamine. However, such treatment only provides symptomatic relief
without hopes for a cure or even a delay in its degeneration. Over the past
decade, there have been increasing studies exploring a potential
connection between PD and gut microbiome. PD is one of the alpha-
synucleinopathies, a group of neurodegenerative disorders associated
with an accumulation of pathologic α-synuclein protein along the brain-gut
axis. The theory that pathologic α-synuclein originates and ascends from
the gut into the brain stems from the presence of common GI symptoms
(abnormal salivation, defecatory dysfunction, dysphagia, constipation, and
nausea) preceding the classical PD motor symptoms. Although the
mechanism behind the theory is still widely unknown, it is suspected that
the propagation of pathologic α-synuclein from the gut to the brain occurs
via the vagal pathway.
Introduction
Methods
A literature search was conducted on Google Scholar and PubMed in
November 2019. Through the search, ten articles were identified with the
highest relevance to the topic. The list was further narrowed down to six
articles and analyzed, identifying those with the highest level of evidence
with clinical relevance to the topic.
Discussion 
Table 1. Comparison of Study Designs
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Results 
Effect of Probiotics Supplementation in the 
Treatment of Parkinson’s Disease
Probiotic supplementation should be considered as an adjunct therapy to
PD treatment regimen. Since probiotics have a generally safe profile, the
benefits likely outweigh the risks in these cases. Future research can
further explore large-scale clinical trials of probiotics use in PD patients.
Long-term studies can also be considered to study the effect of probiotics
on disease progression over time.
Conclusion
Table 2. Comparison of Results/Measurement Parameters
Parkinson’s Disease (PD) is a neurodegenerative disease that results
from the depletion of dopamine-secreting nerve cells. The mainstay of
treatment for PD is Levodopa, a precursor to dopamine, which helps
replenish dopamine levels in the body. However, this treatment is not
curative and does not delay disease progression. PD, as an alpha-
synucleinopathy, is hypothesized to have a potential pathway of disease
development and progression through the brain-gut axis. This literature
review investigated the effect of probiotics supplementation in the
treatment of PD. Although the analysis of six articles demonstrated only
one study with definitive benefits of probiotics supplementation in PD, it
was concluded that probiotic supplementation should be considered an
adjunct therapy in PD treatment due to its generally safe profile.
Key: UPDRS = Unified Parkinson’s Disease Rating Scale; MOCA-J = Montreal Cognitive Assessment (Japanese version); HY = Hoehn and Yahr
scale; LBP = lipopolysaccharide-binding protein; RCT = Randomized Control Trial; MDS-UPDRS = Movement Disorders Society-Unified 
Parkinson’s Disease Rating Scale; CRP = C-reactive protein; MDA = malondialdehyde; GSH = glutathione; SCFA = short chain fatty acids
1 Supplement contains Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus reuteri, and Lactobacillus fermentum.
Study Change in gut 
microbiota 
composition
[MDS]-UPDRS SCFA CRP MDA GSH Insulin LBP
Bedarf et al. 
(2017)
S NS NA NA NA NA NA NA
Hill-Burns et al. 
(2017)
S NS S NA NA NA NA NA
Minato et al. 
(2017)
S S NA NA NA NA NA NS
Scheperjans et 
al. (2015)
S NS NA NA NA NA NA NA
Tamtaji et al. 
(2018)
NA S NA S S S S NA
Unger et al. 
(2016)
S NA S NA NA NA NA NA
Key: S = significant; NS = not significant; NA = not available/measured
Change in gut 
microbiota 
composition 
S = significant 
difference of gut 
micro in study vs 
control group




S = difference in 
UPDRS (P<0.05) 





S = reduced in 
PD pts 
NS = no 
reduction in 
PD   
CRP
S = reduced 
CRP (P<0.05) 
w/ probiotics




S = reduced 
MDA (P<0.05) 
w/ probiotics




S = increased GSH 
(P<0.05) w/ 
probiotics
NS = no reduction 
in GSH levels 
Insulin












NS = no reduction 
in LBP
While only one article had directly assessed the effect of probiotic
supplements on PD patients and concluded that probiotics had favorable
effects on multiple parameters of PD (including significantly decreased
UPDRS scores, reduced sensitivity to CRP (C-reactive protein), and
reduced insulin levels and resistance with a rise in insulin sensitivity),
other studies provided supporting evidence of an association between
certain microbial groups and severity of PD symptoms. Notably, a
statistically significant reduction in Prevotellaceae, Bacteroidetes,
Bacteroides, Erysipelotrichaceae, Clostridium leptium, Faecalibacterium,
Lactobacillaceae, and Enterococcaceae were identified in PD patients
when compared to their control group counterparts. In contrast, there was
an increase in Verrucomicrobiaceae, Firmicutes, Ruminococcaceae, and
Enterobacteriaceae in PD microbiome. In one study, Enterobacteriaceae
was noted to have a positive correlation with the severity of postural
instability and gait difficulty in PD while another study associated
diminishing Bacteroides fragilis levels with worsening UPDRS scores.
